ZIVO · XBRL financial data

Zivo Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ZIVO's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025
Revenue	0*	0	4	12	12*	36	0	32	year only	0	53	66
Revenue from contracts with customers	0*	0	4	12	12*	36	0	32	year only	0	53	66
Cost of goods and services sold	0*	0	1	8	8*	23	0	22	year only	0	35	44
Gross profit	0*	0	3	4	4*	13	0	9	—	0	18	21
Research and development	519*	402	442	221	312*	313	2,252	326	243*	2,769	480	203
General and administrative	2,118*	1,568	1,385	1,356	1,588*	976	5,977	1,943	1,380*	1,440	1,171	836
Total operating expenses	2,638*	1,970	1,827	1,577	1,901*	1,288	8,230	2,269	1,623*	4,209	1,651	1,040
Operating income (loss)	(2,638)*	(1,970)	(1,824)	(1,572)	(1,897)*	(1,276)	(8,230)	(2,260)	(1,596)*	(4,209)	(1,633)	(1,018)
Interest expense	3*	3	32	33	(44)*	3	7	9	—	2	7	13
Other income (expense)	—	—	—	—	—	—	—	(9)	—	—	—	(15)
Income tax expense (benefit)	—	0	0*	0*	—	0	0*	0*	—	—	—	—
Net income (loss)	(2,641)*	(1,973)	(2,071)	(1,825)	(1,909)*	(1,278)	(8,236)	(2,269)	(1,601)*	(4,211)	(1,640)	(1,033)
Earnings per share, diluted USD per share	—	—	—	—	—	(0.47)	(2.78)	(0.67)	(0.45)*	(1.12)	(0.43)	(0.27)
Weighted average shares, diluted thousands of shares	—	—	—	—	—	2,748	2,962	3,410	3,541*	3,750	3,810	3,817

Fiscal quarters (ZIVO's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025
Cash and cash equivalents	1,799	209	21	1,485	274	139	2	159	1,542	517	10	57
Prepaid and other current assets	102	720	509	461	147	568	493	249	91	506	366	224
Total current assets	1,902	928	530	1,948	425	711	495	437	1,635	1,023	410	281
Property and equipment, net	0	0	0	0	0	—	—	—	—	—	—	—
Right-of-use asset	189	168	145	122	98	74	48	22	0	301	286	270
Total assets	2,123	1,128	710	2,102	556	816	576	496	1,643	1,331	703	559
Accounts payable	491	670	1,273	644	993	706	1,093	788	547	655	861	993
Accrued liabilities	398	564	682	824	1,149	1,288	1,003	1,130	1,096	1,224	1,434	1,614
Total current liabilities	2,028	2,791	3,804	3,174	2,762	3,085	2,871	2,579	2,042	2,613	2,960	3,614
Lease liability, non-current	106	79	51	22	0	—	—	—	116	81	238	220
Total liabilities	2,134	2,870	3,855	3,196	2,762	3,085	2,871	2,579	2,158	2,949	3,244	3,846
Accumulated deficit	(115,805)	(117,778)	(119,848)	(121,673)	(123,582)	(124,860)	(133,097)	(135,365)	(136,967)	(141,178)	(142,818)	(143,851)
Total stockholders' equity	(11)	(1,742)	(3,145)	(1,094)	(2,206)	(2,269)	(2,296)	(2,083)	(515)	(1,617)	(2,541)	(3,287)
Total liabilities and equity	2,123	1,128	710	2,102	556	816	576	496	1,643	1,331	703	559
Common shares outstanding (cover page) thousands of shares	9,420	9,420	10,450	1,820	2,778	2,832	3,366	3,546	3,759	3,814	3,817	3,889

Fiscal quarters (ZIVO's year ends in late December)

In thousands of dollars	Q4 FY22Dec 31, 2022	Q1 FY23Mar 31, 2023	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025
Net income (loss)	(2,641)*	(1,973)	(2,071)	(1,825)	(1,909)*	(1,278)	(8,236)	(2,269)	(1,601)*	(4,211)	(1,640)	(1,033)
Stock-based compensation	(1,289)*	—	228	241	(621)*	—	—	—	year only	—	—	—
Net cash from operating activities	(1,447)*	(2,129)	(986)*	(1,970)*	(716)*	(1,699)	(624)*	(1,085)*	(906)*	(1,430)	(476)*	(267)*
Net cash from investing activities	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*	0*
Proceeds from issuing common stock	0*	—	—	—	year only	131	1,633*	1,414	2,424*	—	150	245
Proceeds from issuing equity	50*	—	—	—	—	—	—	—	—	—	—	—
Repayments of long-term debt	—	—	—	—	—	0	0*	—	—	34	34*	—
Net cash from financing activities	(140)*	538	798*	3,433*	(495)*	1,563	487*	1,242*	2,289*	405	(31)*	314*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Zivo Bioscience	57	66	(267)*	3.9M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Regen BioPharma	0.2	59	(24)*	1.7B	0.0 quarters	Q3 FY26 10-QJun 30, 2026
One World Products	169	50	(145)*	120.1M	1.2 quarters	Q3 FY25 10-QSep 30, 2025
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Parabilis Medicines	1,087,060	148	not reported	121.9M	—	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.